Format

Send to

Choose Destination
J Gynecol Oncol. 2018 Mar;29(2):e31. doi: 10.3802/jgo.2018.29.e31.

Major clinical research advances in gynecologic cancer in 2017.

Author information

1
Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea.
2
Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
3
Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea.
4
Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
5
Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea. kjwksh@snu.ac.kr.

Abstract

In 2017, 10 topics were selected as major clinical research advances in gynecologic oncology. For cervical cancer, efficacy and safety analysis results of a 9-valent human papillomavirus (HPV) vaccine and long-term impact of reduced dose of quadrivalent vaccine were updated. Brief introduction of KEYNOTE trials of pembrolizumab, a monoclonal antibody that blocks the interaction between programmed death (PD)-1 and its ligands, PD-L1 and PD-L2, followed. Tailored surveillance programs for gynecologic cancer related with Lynch syndrome and update on sentinel lymph node mapping were reviewed for uterine corpus cancer. For ovarian cancer, 5 topics were selected including poly(ADP-ribose) polymerases inhibitors and immunotherapy. The other potential practice changers covered in this review were lymphadenectomy in advanced disease, secondary cytoreductive surgery in recurrent disease, weekly dose-dense regimen for first-line chemotherapy, incorporation of bevacizumab maintenance in platinum-sensitive recurrent disease, and effect of platinum-free interval prolongation. Conflicting opinions of academic societies on periodic pelvic examination were introduced in conjunction with relevant literature review. For the field of radiation oncology, results of 2 big trials, The Postoperative Radiation Therapy in Endometrial Carcinoma-3 and Gynecologic Oncology Group-258, for endometrial cancer and recent advance in high-dose-rate brachytherapy for cervical cancer were reported. Topics for breast cancer covered adjuvant capecitabine after preoperative chemotherapy, adjuvant pertuzumab and trastuzumab in early human epidermal growth factor receptor 2-positive disease, olaparib for metastatic cancer in patients with a germline BRCA mutation, 20-year risks of recurrence after stopping endocrine therapy at 5 years, and contemporary hormonal contraception and the risk of breast cancer.

KEYWORDS:

Breast Neoplasms; Immunotherapy; Molecular Targeted Therapy; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors

PMID:
29468855
PMCID:
PMC5823987
DOI:
10.3802/jgo.2018.29.e31
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology Icon for PubMed Central
Loading ...
Support Center